Streamex Corp., formerly known as BioSig Technologies, Inc., reported significant financial changes in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no revenue for the three and nine months ended September 30, 2025, a decline from $27,000 in revenue during the same period in 2024. The net loss attributable to common shareholders increased to $15.6 million for the third quarter and $38.8 million for the nine months, compared to losses of $1.9 million and $9.4 million, respectively, in the prior year. This substantial increase in losses is attributed to higher operating expenses, particularly in general and administrative costs, which rose by 67% to $4.6 million in the third quarter, driven by professional fees related to the acquisition of Streamex Exchange.
The company’s financial position has also changed dramatically, with total assets increasing to approximately $130.5 million as of September 30, 2025, up from $842,000 at the end of 2024. This increase is primarily due to the acquisition of Streamex Exchange, which added significant intangible assets and goodwill, totaling $115.5 million. Current liabilities surged to $125.6 million, largely due to a derivative liability of $115.7 million associated with the Exchangeable Shares issued during the acquisition. The company reported a working capital deficit of $111 million, raising concerns about its ability to continue as a going concern.
Strategically, Streamex Corp. has shifted its focus from medical device technology to digital infrastructure for commodity trading and finance, following the acquisition of Streamex Exchange on May 28, 2025. This acquisition is expected to enhance the company’s product offerings and accelerate its integration into blockchain technologies. The company is currently developing a blockchain-based platform for tokenizing real-world assets, with an initial focus on gold-backed financial products. However, as of the reporting date, Streamex Exchange remains in the development stage and has not yet generated revenue.
Operationally, the company has seen a significant increase in its employee headcount, reflecting its strategic expansion. As of September 30, 2025, the company had 35.5 million shares of common stock outstanding, a substantial increase from 17.2 million shares at the end of 2024. The company is actively exploring various funding sources to support its operations, including public or private equity offerings and strategic partnerships. However, it faces substantial uncertainty regarding its ability to generate sufficient cash flow to fund operations in the future.
Looking ahead, Streamex Corp. anticipates continued operating losses and negative cash flows until its products achieve commercial success. The company is focused on launching its tokenized gold financing product, which is currently under development, and expects to incur additional costs related to platform development and regulatory compliance. The management has expressed the need for additional financing to support ongoing operations and has entered into agreements for secured convertible debentures and equity purchases to address its capital requirements. However, the company acknowledges that there can be no assurance that it will successfully secure the necessary funding.
About BioSig Technologies, Inc.
BioSig Technologies, Inc. develops advanced medical device technology focused on electrophysiology (EP) with its PURE EP™ Platform, which enhances real-time cardiac signal acquisition and analysis during catheter ablation of complex arrhythmias like atrial fibrillation and ventricular tachycardia. Serving electrophysiologists and EP labs, BioSig’s platform improves signal clarity and procedural precision, aiming to optimize ablation outcomes through proprietary hardware and software integrated into existing clinical workflows.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.